Dimensional Fund Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Dimensional Fund Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.98M	Buy	716,986 +223,562	+45%	+$556K	﹤0.01%	2708
2026 Q2	$1.15M	Buy	493,424 +196,581	+66%	+$416K	﹤0.01%	2837
2026 Q1	$644K	Buy	296,843 +268,099	+933%	+$665K	﹤0.01%	2912
2025 Q4	$51.5K	Buy	28,744 +11,716	+69%	+$24K	﹤0.01%	3208
2025 Q3	$37.5K	Sell	17,028 -28,543	-63%	-$46.5K	﹤0.01%	3249
2025 Q2	$67.7K	Buy	+45,571	New	+$93.2K	﹤0.01%	3215

Other funds holding PLX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Dimensional Fund Advisors's PLX Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Protalix BioTherapeutics (PLX) stake by 45% in Q3 2026, buying an estimated $556K and bringing the position to 716,986 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

Dimensional Fund Advisors first reported a position in PLX in Q2 2025 and has held it in 6 quarters since. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Dimensional Fund Advisors held 716,986 shares of Protalix BioTherapeutics worth $1.98M as of Q3 2026.
Dimensional Fund Advisors bought 223,562 Protalix BioTherapeutics shares in Q3 2026, an estimated $556K.
Protalix BioTherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2708 holding.
Dimensional Fund Advisors first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 6 quarters since.
48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.